Clinical Trials

A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment


Study ID
Novartis CPZP034A2410

NCT Number
NCT03200717 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0610

Principle Investigator
Dr. Robert Alter

Phase
II

Sponsor
Novartis


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now